Skip to main content
OpenTrials

Clinical trial condition

Purpura

Explore clinical trials studying Purpura. Study availability and eligibility vary by location and protocol.

385 public trials 105 recruiting studies
Refine in advanced search Browse all conditions

Purpura trial results

Completed

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076399

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations
  • Arizona Oncology Associates Tucson, Arizona, United States
  • University of Southern California Los Angeles, California, United States
  • Lakeland Regional Cancer Center Lakeland, Florida, United States
  • Bleeding & Clotting Disorders Institute Peoria, Illinois, United States
View all 52 locations
View Trial Details
Completed

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

NCT00718692

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations
  • Univ Nebraska Med Ctr. UNMC, 1005 Omaha, Nebraska, United States
  • Hospital of the University of Pennsylvania, Site 1002 Philadelphia, Pennsylvania, United States
  • 2085 Henry Tecklenburg Drive, 1001 Charleston, South Carolina, United States
  • Research Site 3203 Bruges, Belgium
View all 59 locations
View Trial Details
Completed

A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

NCT02076412

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations
  • Hematology Oncology Associates of Rockland Division of Highland Medical PC Nyack, New York, United States
  • Medizinische Universitaet Wien / AKH Wien Vienna, AU, Austria
  • Hanusch-Krankenhaus Wiener Gebietskrankenkasse Vienna, AU, Austria
  • LKH Feldkirch at LKH Rankweil Rankweil, Austria
View all 35 locations
View Trial Details
Completed

Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

NCT00625443

Conditions
Autoimmune Diseases, Blood Coagulation Disorders, Blood Platelet Disorders, +16 more
Locations
  • Pacific Cancer Medical Center, Inc Anaheim, California, United States
  • Comprehensive Blood and Cancer Center Bakersfield, California, United States
  • Davis, Posteraro and Wasser, MDs, LLP Manchester, Connecticut, United States
  • Florida Cancer Institute New Port Richey, Florida, United States
View Trial Details

Related conditions